Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,006 public trials 571 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Completed

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

NCT02375555

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Emory University Atlanta, Georgia, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View Trial Details
Completed

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

NCT01943851

Conditions
Blood Protein Disorders, Bone Marrow Diseases, Cardiovascular Diseases, +19 more
Locations
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Aurora, Colorado, United States
  • GSK Investigational Site New York, United States
  • GSK Investigational Site Philadelphia, Pennsylvania, United States
View all 15 locations
View Trial Details
Completed

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

NCT02939183

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Research Site West Hollywood, California, United States
  • Research Site Tampa, Florida, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site Chicago, Illinois, United States
View all 20 locations
View Trial Details
Completed

Quality of Life the Danish Multiple Myeloma Patients

NCT02892383

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Sygehus Sønderjylland Aabenraa, Denmark
  • Aalborg University Hospital Aalborg, Denmark
  • Aarhus University Hospital Aarhus, Denmark
  • Rigshospitalet Copenhagen, Denmark
View Trial Details
Completed

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

NCT02616640

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Local Institution - 102 Baltimore, Maryland, United States
  • Local Institution - 114 Boston, Massachusetts, United States
  • Local Institution - 108 Boston, Massachusetts, United States
  • Local Institution - 115 Boston, Massachusetts, United States
View all 22 locations
View Trial Details
Completed

Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

NCT05199337

Conditions
AL Amyloidosis, Amyloidosis, Immune System Diseases, +10 more
Locations
  • University of Southern California Los Angeles, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Tulane University New Orleans, Louisiana, United States
  • Washington University St Louis, Missouri, United States
View all 21 locations
View Trial Details
Completed

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

NCT02633059

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chromosome 17 deletion, +15 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
View Trial Details

Related conditions